NCT03894670

Brief Summary

The wireless motility capsule technology, SmartPill™, can be used to assess gastric emptying and gastrointestinal (GI) transit time. The SmartPill is usually ingested together with a SmartBar™ which is a snack bar with a nutrient composition that differs substantially from a normal western diet. The primary aim of the present study is to compare effects of a SmartBar™ and a standard mixed meal on gastric emptying and GI motility.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
15

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Oct 2018

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 16, 2018

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

March 12, 2019

Completed
16 days until next milestone

First Posted

Study publicly available on registry

March 28, 2019

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 24, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 24, 2019

Completed
Last Updated

June 18, 2019

Status Verified

June 1, 2019

Enrollment Period

7 months

First QC Date

March 12, 2019

Last Update Submit

June 17, 2019

Conditions

Keywords

Gastric emptyingGastrointestinal transitFood rewardFood preferences

Outcome Measures

Primary Outcomes (1)

  • Gastric emptying time (minutes)

    Measured by the SmartPill™ technique. The SmartPill™ is ingested at both visits in combination with the standard breakfast meal and SmartBar™, respectively. The time frame depends on the individual gastric emptying time.

    Within 24 hours from ingestion of the SmartPill™ at both visits (standard breakfast meal and SmartBar™, respectively)

Secondary Outcomes (57)

  • Small bowel transit time (minutes)

    Within 5 days after both visits (standard breakfast meal and SmartBar™, respectively)

  • Large bowel transit time (minutes)

    Within 5 days after both visits (standard breakfast meal and SmartBar™, respectively)

  • Total gastrointestinal transit time (minutes)

    Within 5 days after both visits (standard breakfast meal and SmartBar™, respectively)

  • Motility index (arbitrary unit)

    Within 5 days after both visits (standard breakfast meal and SmartBar™, respectively)

  • Metabolites

    0 minutes (fasting) and 15, 30, 45, 60, 90, 120, 180, 240 minutes (after consumption of the standard breakfast meal and SmartBar™, respectively)

  • +52 more secondary outcomes

Study Arms (2)

SmartBar™

ACTIVE COMPARATOR

The wireless capsule technology, SmartPill™, is usually ingested together with a SmartBar™ which is a snack bar with a nutrient composition that differs substantially from a normal western diet.

Other: SmartBar™

Standard mixed breakfast meal

EXPERIMENTAL

The SmartPill™ is ingested together with a standard mixed breakfast meal and the outcomes of interest will be compared with the SmartBar™ condition (reference).

Other: Standard mixed breakfast meal

Interventions

The standard mixed breakfast meal consists of: 150 g yoghurt, 20 g muesli; 50 g wheat bun; 22 g rye bread; 25 g cheese; 25 g marmalade; 8 g butter; Total energy content: 500 kcal Macronutrient composition: 34 E% fat, 17 E% protein, 49 E% carbohydrate

Standard mixed breakfast meal

SmarBar™ (Medtronic, North Haven, MA, USA). Weight: 72 g; Total energy content: 260 kcal Macronutrient composition: 7 E% fat, 19 E% protein, 74 E% carbohydrate.

SmartBar™

Eligibility Criteria

Age30 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Body mass index: 18.5 to 24.9 kg/m2

You may not qualify if:

  • Unable to understand the informed consent and the study procedures;
  • Self-reported history of an eating disorder in the past three years
  • HbA1c: ≥5.7 % (≥39 mmol/mol)
  • Uncontrolled medical issues including but not limited to cardiovascular pulmonary, rheumatologic, hematologic, oncologic, infectious, GI or psychiatric disease; diabetes or other endocrine disease; immunosuppression
  • Current treatment with medication or medical devices which affect GI motility and transit time (prokinetics, antidiarrheals, laxatives)
  • Current treatment with medication which affect glucose metabolism or appetite
  • Current treatment with beta blockers or peroral steroids
  • Current treatment with non-steroidal anti-inflammatory drugs, tricyclic antidepressants, selective serotonin re-uptake inhibitors or opioids
  • Bariatric surgery
  • GI symptoms or diseases such as regular (weekly) abdominal pain, dysphagia, gastric bezoars, strictures, fistulas, bowel obstructions, diverticulitis, celiac disease, Crohn's disease, ulcerative colitis or proctitis
  • Pregnant or lactating women
  • Fertile women not using birth control agents including oral contraceptives, gestagen injection, subdermal implants, hormonal vaginal ring, transdermal application, or intra-uterine devices
  • Concomitant participation in other research studies

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Steno Diabetes Center Copenhagen

Gentofte Municipality, DK-2810, Denmark

Location

Related Publications (1)

  • Jensen MM, Pedersen HE, Clemmensen KKB, Ekblond TS, Ried-Larsen M, Faerch K, Brock C, Quist JS. Associations Between Physical Activity and Gastrointestinal Transit Times in People with Normal Weight, Overweight, and Obesity. J Nutr. 2024 Jan;154(1):41-48. doi: 10.1016/j.tjnut.2023.06.005. Epub 2023 Jun 12.

MeSH Terms

Conditions

Food Preferences

Condition Hierarchy (Ancestors)

Feeding BehaviorBehavior

Study Officials

  • Kristine Færch, PhD

    Steno Diabetes Center Copenhagen

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
CROSSOVER
Model Details: The study is a randomized cross-over study including 15 healthy normal-weight individuals. On two separate test days participants ingest the SmartPill™ in combination with a SmartBar™ (standard procedure, reference) or a standard mixed breakfast meal.
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Senior Researcher and Team Leader, PhD

Study Record Dates

First Submitted

March 12, 2019

First Posted

March 28, 2019

Study Start

October 16, 2018

Primary Completion

May 24, 2019

Study Completion

May 24, 2019

Last Updated

June 18, 2019

Record last verified: 2019-06

Locations